Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
前日終値
$80.65
+$3.37 · +4.36%
時間外
$81.12
+$0.47 · +0.58%
10月9日 19:53 ET
日中の時刻はETです。市場データは遅延する場合があります。
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
日中レンジ
現在 $80.65
52週レンジ
現在 $80.65
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
66
割安
センチメント
45
まちまち
リスク
48
やや高いリスク
モメンタム
72
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
日中レンジ
現在 $80.65
52週レンジ
現在 $80.65
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6.43億 USD | 6.11億 USD | 6.19億 USD | 5.16億 USD | 4.9億 USD |
| 売上原価 | 1.99億 USD | 1.96億 USD | 2.09億 USD | 1.2億 USD | 7409.1万 USD |
| 粗利益 | 4.44億 USD | 4.14億 USD | 4.09億 USD | 3.96億 USD | 4.16億 USD |
| 研究開発 | 2.39億 USD | 2.65億 USD | 2.7億 USD | 2.66億 USD | 2.12億 USD |
| 販売・一般管理 | 3.16億 USD | 3.44億 USD | 3.43億 USD | 2.98億 USD | 2.58億 USD |
| 営業費用 | 5.55億 USD | 6.09億 USD | 6.75億 USD | 5.64億 USD | 4.69億 USD |
| 受取利息 | 2004.8万 USD | 1844.8万 USD | 1690.6万 USD | 664.7万 USD | 20.6万 USD |
| 支払利息 | — | 4000 USD | 3.3万 USD | 47.6万 USD | 86.6万 USD |
| 減価償却費と償却費 | 4381.6万 USD | 4370.8万 USD | 4361.9万 USD | 3300.6万 USD | 2825.4万 USD |
| 営業利益 | −1.11億 USD | −1.95億 USD | −2.65億 USD | −1.68億 USD | −5291.3万 USD |
| 純利益 | −4354.4万 USD | −1.83億 USD | −2.55億 USD | −1.66億 USD | −5822.3万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$74.30
下落余地(7.87%)| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2006年7月17日 | 1:2 | — | — |
発効済み 2006年7月17日
1:2
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM2.38億0.30%782.66億 USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI2.2億0.01%2.3兆 USD0.03%$381.94+0.63%
ARK Genomic Revolution ETFARKG1.89億9.23%15.57億 USD0.75%$51.30+4.08%
ARK Innovation ETFARKK1.87億2.72%55.62億 USD0.75%$89.62+2.31%
Vanguard Morningstar Small-Cap ETFVB1.6億0.09%1853億 USD0.03%$289.48+0.64%
Vanguard Morningstar Small-Cap Growth ETFVBK9157.53万0.20%447億 USD0.05%$344.74+1.22%
Vanguard Extended Market ETFVXF8481.65万0.09%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO8362.31万0.61%139.72億 USD0.24%$356.78+0.94%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
ARK Genomic Revolution ETFARKG
ARK Innovation ETFARKK
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Growth ETFVBK
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWOAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。